Epigenetic Regulation of EMT in Non-Small Cell Lung Cancer

Author(s): Karen O’Leary, Alice Shia, Peter Schmid*

Journal Name: Current Cancer Drug Targets

Volume 18 , Issue 1 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Lung cancer remains the most diagnosed cancer in the world, with a high mortality rate and fewer therapeutic options. The most common lung cancer is non-small cell, consisting of adenocarcinoma, squamous cell carcinoma and large cell lung carcinoma. As per all solid tumours, the changes that occur for the initiation and metastasis of lung cancer can be described using the EMT (epithelial mesenchymal transition). Cells progressing through EMT lose their epithelial cell characteristics, expressing more mesenchymal markers and are phenotypically different. The transition can be controlled by changes in various pathways, such as TGF-β, PI3K, MAPK, Hedgehog and Wnt. The changes in those pathways can be controlled epigenetically, via DNA methylation, histone modifications or changes in small/non-coding RNA. We will describe the epigenetic changes that occur in these pathways and how we can consider novel methods to generate a synthetic lethality target in an epigenetically regulated pathway in EMT.

Keywords: NSCLC, EMT regulation, epigenetics, targeted therapy, lung cancer, tumor.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 03 February, 2017
Page: [89 - 96]
Pages: 8
DOI: 10.2174/1568009617666170203162556
Price: $65

Article Metrics

PDF: 113
HTML: 22